Covid-19: US regulator raises “significant concerns” over safety of rapid lateral flow testsBMJ 2021; 373 doi: https://doi.org/10.1136/bmj.n1514 (Published 14 June 2021) Cite this as: BMJ 2021;373:n1514
Diagnostic tests must be more rigorously regulated
- Gareth Iacobucci
- The BMJ
The US Food and Drug Agency (FDA) has raised concerns about the safety and the marketing of rapid lateral flow covid-19 tests, which are the cornerstone of the UK’s mass testing programme.
On 10 June,1 the agency warned the public to stop using the Innova SARS-CoV-2 antigen rapid qualitative test for detecting infection and suggested the tests should be destroyed and binned or returned to the manufacturer.
The FDA published a class 1 recall of the test after an investigation carried out between March and April uncovered “significant concerns that the performance of the test has not been adequately established, presenting a risk to health.” Class 1 is the most serious kind of recall and indicates that use of the tests may cause serious injury or death.
In addition, the FDA said that “labelling distributed with certain configurations of …
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.